NASDAQ:ANIK - Anika Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.50
  • Forecasted Upside: 5.85 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$42.04
▲ +0.46 (1.11%)

This chart shows the closing price for ANIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anika Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIK

Analyst Price Target is $44.50
▲ +5.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $44.50, with a high forecast of $46.00 and a low forecast of $43.00. The average price target represents a 5.85% upside from the last price of $42.04.

This chart shows the closing price for ANIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Anika Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/30/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/29/2020
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2021UBS GroupInitiated CoverageNeutral$46.00Low
12/16/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$43.00High
5/8/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
2/21/2020Barrington ResearchReiterated RatingBuy$60.00Low
1/21/2020SidotiUpgradeNeutral ➝ Buy$61.00Low
1/10/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$65.00Low
11/5/2019BWS FinancialInitiated CoverageSell$29.00High
10/25/2019SidotiSet Price TargetHold$50.00N/A
9/24/2019Barrington ResearchReiterated RatingOutperform$49.00 ➝ $58.00Medium
9/23/2019First AnalysisDowngradeStrong-Buy ➝ Outperform$54.00Low
7/25/2019Barrington ResearchReiterated RatingBuy$45.00 ➝ $49.00High
7/25/2019First AnalysisUpgradeNeutral ➝ Strong-Buy$37.00 ➝ $54.00High
3/5/2019SidotiSet Price TargetHold$35.00Low
2/28/2019Singular ResearchReiterated RatingBuyMedium
2/22/2019Barrington ResearchLower Price TargetOutperform$44.00High
2/22/2019SidotiDowngradeBuy ➝ Neutral$56.00 ➝ $41.00High
2/22/2019First AnalysisDowngradeOutperform ➝ Neutral$41.00 ➝ $37.00High
7/27/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$48.00Medium
6/20/2018Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
6/20/2018First AnalysisDowngradeOverweight ➝ Equal Weight$45.00 ➝ $34.00High
5/4/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$39.00High
2/23/2018Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
1/26/2018SidotiInitiated CoverageBuyLow
1/24/2018First AnalysisUpgradeEqual Weight ➝ Overweight$45.00 ➝ $68.00High
12/28/2017Barrington ResearchReiterated RatingBuy$57.00Low
10/27/2017Barrington ResearchBoost Price TargetOutperform ➝ Outperform$53.00 ➝ $57.00N/A
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/24/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/23/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/22/2021

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Anika Therapeutics logo
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Read More

Today's Range

Now: $42.04
Low: $41.35
High: $42.18

50 Day Range

MA: $41.01
Low: $38.75
High: $43.30

52 Week Range

Now: $42.04
Low: $32.04
High: $48.37

Volume

1,743 shs

Average Volume

105,606 shs

Market Capitalization

$606.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Anika Therapeutics?

The following Wall Street research analysts have issued reports on Anika Therapeutics in the last year: Barrington Research, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for ANIK.

What is the current price target for Anika Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Anika Therapeutics in the last year. Their average twelve-month price target is $44.50, suggesting a possible upside of 5.9%. UBS Group AG has the highest price target set, predicting ANIK will reach $46.00 in the next twelve months. Barrington Research has the lowest price target set, forecasting a price of $43.00 for Anika Therapeutics in the next year.
View the latest price targets for ANIK.

What is the current consensus analyst rating for Anika Therapeutics?

Anika Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIK will outperform the market and that investors should add to their positions of Anika Therapeutics.
View the latest ratings for ANIK.

What other companies compete with Anika Therapeutics?

How do I contact Anika Therapeutics' investor relations team?

Anika Therapeutics' physical mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company's listed phone number is (781) 457-9000 and its investor relations email address is [email protected] The official website for Anika Therapeutics is www.anikatherapeutics.com.